Monopar Therapeutics Stock Jumps 4X, Inks Licensing Pact With AstraZeneca For Once Terminated Phase 3 Candidate For Rare Genetic Disorder

Monopar Therapeutics Inc. MNPR stock is skyrocketing on Thursday. The company agreed with AstraZeneca Plc's AZN Alexion for an exclusive worldwide license to ALXN-1840 (bis-choline tetrathiomolybdate) for Wilson's disease. Monopar will be responsible for all future global development and commercialization activities. Also Read: Why Monopar Therapeutics (MNPR) Stock Is Skyrocketing Today Under the terms of the license agreement, Monopar will pay Alexion an upfront cash payment and equity in Monopar. Future p ...